Kunming Longjin Pharmaceutical Co., Ltd. Stock

Equities

002750

CNE1000021X8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
3.67 CNY -4.92% Intraday chart for Kunming Longjin Pharmaceutical Co., Ltd. -19.34% -63.30%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 123M 17.02M Sales 2023 86.62M 11.99M Capitalization 4B 554M
Net income 2022 -56M -7.75M Net income 2023 -70M -9.69M EV / Sales 2022 33 x
Net cash position 2022 403M 55.82M Net cash position 2023 333M 46.13M EV / Sales 2023 42.4 x
P/E ratio 2022
-79.4 x
P/E ratio 2023
-56.5 x
Employees 262
Yield 2022 *
-
Yield 2023
-
Free-Float 41.99%
More Fundamentals * Assessed data
Dynamic Chart
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kunming Longjin Pharmaceutical Co., Ltd. Approves Board Elections CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Kunming Longjin Pharmaceutical's Shareholder Plans to Cut 6% Stake CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021 CI
More news
1 day-4.92%
1 week-19.34%
Current month-37.48%
1 month-38.32%
3 months-29.69%
6 months-66.79%
Current year-63.30%
More quotes
1 week
3.67
Extreme 3.67
4.32
1 month
3.67
Extreme 3.67
6.02
Current year
3.67
Extreme 3.67
11.50
1 year
3.67
Extreme 3.67
12.50
3 years
3.67
Extreme 3.67
24.33
5 years
3.67
Extreme 3.67
24.33
10 years
3.67
Extreme 3.67
26.55
More quotes
Managers TitleAgeSince
Founder 72 96-09-15
Chief Executive Officer 38 16-01-31
Chairman 48 08-07-31
Members of the board TitleAgeSince
Founder 72 96-09-15
Director/Board Member 65 08-07-27
Director/Board Member 50 02-12-31
More insiders
Date Price Change Volume
24-05-17 3.67 -4.92% 17,293,050
24-05-16 3.86 -1.03% 36,695,620
24-05-15 3.9 -4.88% 1,364,200
24-05-14 4.1 -5.09% 88,800
24-05-13 4.32 -5.05% 92,800

End-of-day quote Shenzhen S.E., May 16, 2024

More quotes
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002750 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW